INVO Fertility Q3 revenue up 23% to $1.76M; net loss widens to $2.6M

INVO Fertility, Inc.

2025-Q3 EPS reported -$17.83 revenue$5,257,933

Revenue $1,757,094 (+23% YoY); clinic revenue $1,722,223 (+21% YoY).
Net loss $(2.6)M vs $(1.6)M; Adjusted EBITDA $(947,568) vs $(945,949).
INVOcell device revenue grew 130% YoY on training support and pricing.
Company expects to complete at least one acquisition in coming months.
Federal policy change in Oct 2025 allows standalone infertility benefits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.